UNSPSC 51182219: Carboprost tromethamine

This classification denotes a prostaglandin analogue with the molecular formula C21H36O5.C4H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U4526F86FJ, chemically known as prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5z,9.alpha.,11.alpha.,13e,15s)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1), but more generally known as carboprost tromethamine, which bears US NIH Compound Identifier 5281074.

UNSPSC 51182219 Carboprost tromethamine is a Commodity code representing a specific pharmaceutical active ingredient used in obstetric and gynecological applications. State and local governments procure this product primarily through cooperative purchasing arrangements that aggregate demand across multiple jurisdictions and healthcare facilities. Recent solicitations show that this code sits within broader multi-source generic pharmaceutical procurement vehicles where state and local health departments, corrections systems, and healthcare networks source finished pharmaceutical products meeting FDA and cGMP standards, rather than carboprost tromethamine as a standalone raw material or active pharmaceutical ingredient. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body visible in recent activity, establishing contracts through cooperative purchasing vehicles that distribute to participating state and local government facilities across multiple states, including Oregon.

The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) on January 20, 2026, closing March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, of which carboprost tromethamine may be one line item among dozens. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and maintain contractual relationships with at least two; all products must be available by May 15, 2026, with contracts effective July 1, 2026. Scoring weights price competitiveness at 75 percent, fixed pricing at 10 percent, and administrative and technical factors at 15 percent combined. Award terms span two years for new vendors with optional extensions, or amendments through June 30, 2028, for incumbents. MMCAP reserves multi-award rights based on therapeutic considerations, product availability, and patient safety needs. No specific set-aside designations are disclosed, and award values are not published.